Polyclonal Antibody to Mineralocorticoid Receptor (MR)
Code | Size | Price |
---|
PAA464Hu01-20ul | 20ul | £81.00 |
Quantity:
PAA464Hu01-100ul | 100ul | £149.00 |
Quantity:
PAA464Hu01-200ul | 200ul | £200.00 |
Quantity:
PAA464Hu01-1ml | 1ml | £454.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
NR3C2; MLR; MCR; Aldosterone Receptor; Nuclear Receptor Subfamily 3 Group C Member 2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Mineralocorticoid Receptor
Reactivity:
Mu;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 1-5ug/mL<br/>Immunocytochemistry in formalin fixed cells: 5-20ug/mL<br/>Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL<br/>Immunohistochemistry in paraffin section: 5-20ug/mL<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Mineralocorticoid Receptor (MR) | RPA464Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||